These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 17917543

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M, Cobankara V, Akpolat T.
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [Abstract] [Full Text] [Related]

  • 4. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM.
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM.
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [Abstract] [Full Text] [Related]

  • 7. Renin-angiotensin system mediators and Raynaud's phenomenon.
    Wood HM, Ernst ME.
    Ann Pharmacother; 2006 Nov; 40(11):1998-2002. PubMed ID: 17003081
    [Abstract] [Full Text] [Related]

  • 8. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R, Shariat K, von Wilmowsky H, Böhm M.
    Circulation; 2005 Nov 08; 112(19):2980-5. PubMed ID: 16275885
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R, Generini S, Luppi F, Pignone A, Matucci-Cerinic M.
    Arthritis Rheum; 2004 Aug 15; 51(4):665-9. PubMed ID: 15334442
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL.
    Ann Pharmacother; 2006 Aug 15; 40(7-8):1388-93. PubMed ID: 16835313
    [Abstract] [Full Text] [Related]

  • 14. Raynaud's phenomenon and systemic sclerosis.
    Generini S, Kahaleh B, Matucci-Cerinic M, Pignone A, Lombardi A, Ohtsuka T.
    Ann Ital Med Int; 1996 Aug 15; 11(2):125-31. PubMed ID: 8974438
    [Abstract] [Full Text] [Related]

  • 15. [Therapeutic management of acral manifestations of systemic sclerosis].
    Meyer MF, Daigeler A, Lehnhardt M, Steinau HU, Klein HH.
    Med Klin (Munich); 2007 Mar 15; 102(3):209-18. PubMed ID: 17345017
    [Abstract] [Full Text] [Related]

  • 16. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P.
    Rev Prat; 1998 Oct 01; 48(15):1659-64. PubMed ID: 9814067
    [Abstract] [Full Text] [Related]

  • 17. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS, Gilgor RS, Allen LM, Duvic M.
    Arch Dermatol; 1984 Mar 01; 120(3):329-31. PubMed ID: 6367665
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F.
    Rheumatology (Oxford); 2006 Oct 01; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.